| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 45 | 22.3x | 17.8x | Around median | |
Growth | 31 | 3.0% | 7.1% | Bottom tier | |
Quality | 62 | 8.3% | 4.5% | Around median | |
Safety | 70 | 1.7x | 2.6x | Top tier | |
Capital Return | 22 | 0.59% | 2.12% | Bottom tier | |
Momentum | 32 | -13.0% | 2.9% | Bottom tier | |
Sentiment | 85 | 9 | 3 | Top tier |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Qiagen N.V. operates in life sciences and molecular diagnostics solutions across four product groups: Sample Technologies, Diagnostic Solutions, PCR and Nucleic Acid Amplification Technologies, and Genomics and Next-Generation Sequencing products. The company generates revenue from the sale of systems and instruments and from recurring demand for consumables and tests; its platforms include QIAsymphony Connect, QIAstat-Dx, QIAcuity, and QuantiFERON, alongside the Qiagen Digital Insights bioinformatics business and Parse single-cell analysis solutions.
In Q2 fiscal 2026, net sales were $535 million, unchanged on a reported basis or at constant exchange rates, but exceeded the company’s outlook for a decline of approximately 2%. Adjusted operating income was $157 million, down 2%, and its margin declined to 29.4% from 29.9%, while the adjusted gross margin fell to 66.2% from 66.7% due to product mix. Adjusted diluted earnings per share were $0.62, exceeding the outlook of at least $0.60.
Performance across the portfolio was mixed in Q2 fiscal 2026: Sample Technologies rose 9% at constant exchange rates, Diagnostic Solutions declined 2%, PCR and Nucleic Acid Amplification Technologies fell 8%, while Genomics and Next-Generation Sequencing products grew 2%. For fiscal 2025, Qiagen reported revenue of $2.1 billion, gross profit of $1.3 billion, net income of $424.9 million, and earnings per share of $1.94, compared with net income of $83.6 million and earnings per share of $0.37 in fiscal 2024.
Automated analysis for informational purposes only — not investment advice.
The analyst consensus on QGEN is Neutral, with an average price target of $42.51 and a target range of $38.60 to $48. The average target lies within the 52-week range of $32.53–$57.82 and is approximately 26% below the top of that range, while the provided data does not include a valid price-to-earnings ratio that could be used as an additional valuation anchor. The valuation therefore reflects a balance between cash flow, profitability, and new launches on one hand, and flat sales, the loss of immigration testing demand, margin pressures, and legal risks on the other.
Figures in the text are as of 2026-08-29; the live price is shown at the top of the page.
Net sales were $535 million, unchanged on a reported basis or at constant exchange rates, but exceeded management’s outlook for a decline of approximately 2%. Sample Technologies rose 9%, driven by automated consumables and higher instrument sales, while QIAcuity achieved double-digit growth due to consumables. In contrast, Diagnostic Solutions declined 2%, PCR and Nucleic Acid Amplification Technologies fell 8%, and adjusted diluted earnings per share were $0.62.
Management expects sales growth at constant exchange rates to improve from negative 1% in the first half to approximately 3%–4% in the second half of fiscal 2026. The end of the impact from the NeuMoDx and DIALUNOX discontinuations is expected to add approximately two percentage points, while new systems and product launches are expected to add approximately two percentage points. The contribution from Parse and a modest improvement in the U.S. life sciences environment add approximately 0.5 percentage points, with growth expected to be weighted toward Q4 fiscal 2026 due to launches and easier comparisons.
QIAstat-Dx sales declined 7% at constant exchange rates in Q2 fiscal 2026 due to weakness in respiratory panels, despite growth in gastrointestinal and meningitis panels. Qiagen expanded the menu by launching two bloodstream infection panels in Europe that detect 33 pathogens and 28 antimicrobial resistance markers in approximately one hour. The company is targeting U.S. Food and Drug Administration approval for both panels by the end of fiscal 2026 and expects high-single-digit or low-double-digit growth for the platform in the second half.
Management continues to target revenue of $500 million for QuantiFERON in fiscal 2026 after the product returned to 1% growth at constant exchange rates in Q2. However, the decline in immigration testing demand resulted in the removal of $35 million from expected revenue, and the company said this market was no longer available to it or its competitors. The plan depends on converting more customers from the traditional skin test to blood-based testing, expanding use among diabetes and dialysis patients, and benefiting from easier comparisons in Q4 fiscal 2026.
On August 28, 2026, a Delaware jury found that Parse Biosciences willfully infringed three patents exclusively licensed to 10x Genomics. Damages exceeded $4.8 million for Evercode sales between February 2021 and June 2026 and were based on a 14% royalty rate. 10x Genomics is seeking additional damages and a permanent injunction, while Qiagen had expected Parse’s contribution to exceed its original sales target of approximately $40 million in fiscal 2026, making the outcome of the dispute important to the trajectory of this business.
